Logo

MDS Sciex Says Q4 Organic Revenues Inched Up 1 Percent

Dec 14, 2006
NEW YORK (GenomeWeb News) — MDS today reported that fourth-quarter revenue for its Sciex division declined 5.5 percent to $69 million from $73 million year over year.
 
The company blamed the decline on currency effects but said organic revenues were up 1 percent.
 
MDS said Sciex’s organic increases came from growth in the small-molecule business and high-end triple quad and trap products, and from growth in India and China.
 
MDS did not break down R&D spending for the Sciex division but said that spending was down year over year because two products, the CellKey System and 4800 platforms have entered commercial production.
 
The company also did not break out earnings or a balance sheet for the unit.

Breaking News
The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.